Diabetes is a worldwide health crisis. Estimates in 2024 revealed 537 million adults aged 20 to 79 are affected by diabetes, and this number is projected to increase to 643 million by 2030. The ...

AMSBIO (Oxford, UK) announces an innovative range of induced pluripotent stem cell (iPSC) kits for researchers requiring a rapid, reproducible, and scalable means of generating specific neural cell ...

Generating specific cell lineages from induced pluripotent stem cells and embryonic stem cells is the holy grail of regenerative medicine. Guiding iPSCs toward a target cell line has garnered much ...

The ability to derive induced pluripotent stem cells (iPSCs) from differentiated cell types such as fibroblasts, has revolutionized drug discovery for many disease areas including neurodegenerative ...

First demonstration of the survival of allogeneic islet cells, cardiomyocytes, and retinal pigment epithelium cells transplanted into an immunocompetent non-human primate model without any immune ...

The progress in induced pluripotent stem cells (iPSCs) and organoid technology has addressed the lack of suitable in vitro models for human neurodevelopmental and degenerative disorders. Over the past ...

This project has reached full capacity for the current term. Please check back next semester for updates. The research in our laboratory is focused, among others, on developmental biology, with a ...

TOKYO & MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and ...

The Stem Cell Differentiation Core provides patient-specific, stem cell-based models that enable investigators to test CFTR function and its rescue through various approaches including, but not ...